Post immunization COVID-19 disease.
Where this comes from
- Record sourced from PubMed, PMID 35516695.
- Also identified by DOI 10.4103/jfmpc.jfmpc_1975_21 and PMC identifier 9067203.
- Licence recorded as CC BY-NC-SA.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
One hundred and two patients reported to peripheral hospital, of these 73 (77%) and 23 (95%) suffered from COVID-19 disease, were immunized as per availability of Covishield 78 (77%) and Covaxin 24 (23%), respectively. Of these, three died (3%). Inflammatory markers were raised in Covishield vs. Covaxin 26 (36%) vs. 7 (31%), 46 (63%) vs. 8 (35%), 57 (78%) vs. 14 (61%), 29 (40%) vs. (73%), C-reactive proteins and serum ferritin, and positive for COVID-19 antigen and RTPCR and COVID-19 pneumonia, respectively. Irrespective of immunization status of victim with symptoms should be investigated for possibility of severe acute respiratory syndrome COVID-beta 2 (SARS-CoV-2) virus infection. These findings confirmed the need for a Booster dose of COVID-19 vaccination.